IMRA - Imara completes enrollment in mid-stage sickle cell disease trial

Imara (NASDAQ:IMRA) announces that the company has completed patient enrollment in the Ardent Phase 2b clinical trial of IMR-687, a potent small molecule inhibitor of PDE9, for the treatment of sickle cell disease (SCD). The company expects to report data from the primary analysis in the first quarter of 2022. The trial is a randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the safety and efficacy of IMR-687 administered once daily in about 99 adult patients with sickle cell disease. The trial is being conducted at approximately 50 sites in 13 different countries. Shares down nearly 1% premarket.

For further details see:

Imara completes enrollment in mid-stage sickle cell disease trial